Cargando…
Erratum for Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255651/ https://www.ncbi.nlm.nih.gov/pubmed/32463988 http://dx.doi.org/10.1111/jvim.15786 |
Ejemplares similares
-
Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
por: Cawley, Jacob R., et al.
Publicado: (2020) -
Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma
por: Thamm, D.H., et al.
Publicado: (2017) -
Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma
por: Weishaar, Kristen M., et al.
Publicado: (2021) -
Erratum to checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?
por: Balzarotti, Monica, et al.
Publicado: (2020) -
Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
por: Foss, Francine, et al.
Publicado: (2017)